Summary
This international clinical trial reports outcomes of atezolizumab monotherapy in patients with advanced or metastatic urothelial carcinoma previously treated with platinum-based chemotherapy. The analysis stratifies efficacy and safety results by the number of prior therapeutic regimens, as suggested by the title, providing evidence on how prior treatment burden may influence immunotherapy response in this patient population.
UK applicability
This oncology trial is not applicable to Vitagri's Pulse Brain focus on farming systems, soil health, and nutrient density. The record appears to have been submitted in error and should be removed from a food and agriculture research catalogue.
Key measures
Overall survival, progression-free survival, response rates, and safety outcomes stratified by prior treatment history
Outcomes reported
The study examined clinical outcomes of atezolizumab (an anti-PD-L1 immunotherapy) in patients with platinum-treated locally advanced or metastatic urothelial carcinoma, stratified by the number of prior chemotherapy regimens received.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.